NCT03962855View on ClinicalTrials.gov

Thromboxane Receptor Antagonist to Improve Endothelial Function

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

November 7, 2022

Study Completion Date

November 15, 2022

Conditions
Cardiovascular DiseasesVascular Dilation
Interventions
DRUG

Ifetroban Sodium

Ifetroban sodium 250 mg capsule once daily for 4 weeks

DRUG

Placebo

Placebo arm to match Ifetroban Sodium once daily for 4 weeks.

Trial Locations (1)

01655

University of Massachusetts Medical School, Worcester

Sponsors
All Listed Sponsors
collaborator

American Heart Association

OTHER

collaborator

Cumberland Pharmaceuticals

INDUSTRY

lead

Jeffrey Rade

OTHER